" "
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

iBio, Inc. and GE Healthcare Form New Global Alliance

Published: Thursday, December 27, 2012
Last Updated: Thursday, December 27, 2012
Bookmark and Share
Companies to commercialize plant-based technologies for biopharmaceutical and vaccine manufacture.

iBio, Inc. and GE Healthcare have announced a new global alliance to commercialize plant-based technologies for the manufacture of biopharmaceuticals and vaccines.

The alliance builds on the existing development and marketing agreement between the two companies announced in 2010 and combines iBio’s innovative plant-based vaccine manufacturing platform, iBioLaunch™, with GE Healthcare’s world-class capabilities in start-to-finish technologies for biopharmaceutical manufacturing.

iBio’s research and development collaborator, Fraunhofer USA Center for Molecular Biotechnology (CMB) will continue to play a key role in advancing the iBioLaunch platform. Financial terms were not disclosed.

The iBioLaunch platform is a proprietary gene expression technology that induces plants to rapidly produce high levels of proteins such as vaccines, in a process which can be easily and reliably scaled-up in low cost, controlled-growth facilities.

GE Healthcare develops and produces world-class start-to-finish technologies and tools used for the manufacture of biopharmaceuticals, vaccines and other protein-based therapeutics.

GE Healthcare’s global team of bioengineers and bioprocessing scientists are working with researchers from iBio and CMB to develop a single, flexible facility which could significantly reduce the capital and operating costs of biotherapeutic and vaccine manufacture compared with traditional animal cell and microbial based methods.

The iBioLaunch platform also has the potential to manufacture proteins which cannot be commercially produced in any other system.

Worldwide demand for biopharmaceuticals and vaccines is increasing dramatically, driven by ageing populations and the global effort to reduce the incidence of vaccine preventable diseases.

In work funded by the Bill & Melinda Gates Foundation, iBio’s pioneering plant-based technology has been used to produce an avian influenza vaccine candidate that recently completed a successful Phase I clinical trial.

The iBioLaunch platform was also used to produce a candidate vaccine against H1N1 influenza, for which a human Phase I trial was successfully completed in March, 2012.

The alliance between the two companies aligns with GE’s healthymagination initiative, which focuses on reducing cost, increasing access and improving quality in healthcare.

“We’re delighted to form this new global alliance with iBio, who share our vision of bringing affordable and flexible manufacturing capabilities to the producers of these vital, lifesaving medicines. We look forward to continuing our work with the talented teams at iBio and CMB to explore how this innovative technology could become a commercial reality,” said Olivier Loeillot General Manager of Enterprise Solutions at GE Healthcare Life Sciences.

Robert B. Kay, Chairman and CEO of iBio, added, “We are delighted to be extending our alliance with GE Healthcare. We look forward to working together on the development of a flexible and cost-effective plant-based manufacturing platform that has the potential to assist in the global effort to increase access to biotherapeutics and help reduce the incidence of vaccine preventable diseases.”

Commenting on the alliance, Dr. Vidadi Yusibov, Executive Director of CMB, said, “We are pleased to continue and extend our relationship with iBio and GE Healthcare. The collective experience and skills of the teams at CMB, iBio and GE Healthcare combined with CMB’s cutting edge pilot facilities in Delaware gives us a great opportunity to accelerate the implementation of this technology.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BeiGene Selects GE’s FlexFactory™ Biomanufacturing Platform
Facility will manufacture biologics for clinical trials.
Wednesday, December 16, 2015
GE Healthcare Licenses CRISPR Gene Engineering Technology Patents
Agreement will drive bioscience research by enabling development of novel Dharmacon genome engineering toolsets.
Tuesday, December 09, 2014
GE Licenses CRISPR Gene Engineering Technology Patents From Broad Institute
Agreement will drive bioscience research by enabling development of novel Dharmacon genome engineering toolsets.
Thursday, December 04, 2014
GE Healthcare and Takeda Join Forces
This alliance is key to enabling the early development of therapeutic drugs through the use of a minimally invasive diagnostic technology.
Thursday, November 13, 2014
GE Healthcare to Collaborate with GlaxoSmithKline on Commercial Oncology Testing
The collaboration aims to improve access to diagnostic testing for cancer patients by establishing a network of clinical laboratories to identify genetic mutations associated with different tumour types.
Tuesday, September 30, 2014
GE Healthcare Life Sciences and Promosome Sign Licensing Agreement
Innovative mammalian cell line development technologies that show promise for increasing manufacturing efficiency of vital biopharmaceuticals.
Tuesday, April 29, 2014
GE Acquires Strategic Assets from Thermo
GE to acquire cell culture media and sera, gene modulation and magnetic beads businesses.
Monday, January 06, 2014
GE Healthcare Acquires Unisyn Medical Technologies’ Transactional Business
The proprietary products and services from Unisyn will be integrated into GE Healthcare’s Global Services organization.
Thursday, May 30, 2013
Winners of GE Healthcare 2012 Cell Imaging Competition Announced
Stunning cellular images to light up Times Square, New York.
Thursday, February 28, 2013
GE Healthcare Launches Modular Biopharmaceutical Factory, KUBio
Innovative approach will save biopharmaceutical manufacturers time and money.
Tuesday, January 15, 2013
GE Healthcare’s 2012 Cell Imaging Competition - Voting Opens to Celebrate Art, Science and Discovery
Competition features both high-content analysis and high- and super-resolution microscopy cell images for the first time.
Thursday, November 22, 2012
GE Healthcare Scientist Paired with Cardiff MP to Share Insights on Cell Therapy, Science and Policy-Making
Dr. Michelle Janas from GE Healthcare Life Sciences visited Jenny Willott MP at the House of Commons for a “Week in Westminster” as part of a unique ‘pairing’ scheme run by the Royal Society.
Thursday, November 15, 2012
GE Healthcare Expands Shanghai Fast Trak Training Center
Expansion adds IN Cell, Biacore and DeltaVision technologies for drug discovery and development.
Monday, September 24, 2012
GE Healthcare Offers Fast Trak Training in Singapore
Fast Trak training and education courses provide practical training in the latest technologies and strategies for bioprocessing.
Tuesday, June 05, 2012
Karolinska University Hospital and GE Healthcare Collaborate to Advance Technologies for Cell Therapy
Pioneering three-year study will investigate technology and workflow needs in a clinical setting.
Wednesday, May 23, 2012
Scientific News
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Genetic Cause of Rare Allergy
Institute has identified a genetic mutation responsible for a rare form of inherited hives induced by vibratory urticaria.
Battery Component Found to Harm Key Soil Microorganism
The material at the heart of the lithium ion batteries that power electric vehicles, laptop computers and smartphones has been shown to impair a key soil bacterium, according to new research.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Mitochondria Shown to Trigger Cell Ageing
An international team of scientists has for the first time shown that mitochondria, the batteries of the cells, are essential for ageing.
Cancer Cells Kill Off Healthy Neighbours
Cancer cells create space to grow by killing off surrounding healthy cells, according to UK researchers working with fruit flies.
Validating the Accuracy of CRISPR-Cas9
IBS Researchers create multiplex Digenome-seq to find errors in CRISPR-Cas9 processes.
Cancer Drug Target Visualized at Atomic Resolution
New study using cryo-electron microscopy shows how potential drugs could inhibit cancer.
Genetic Mechanism Behind Cancer-Causing Mutations
Researchers at Indiana University has identified a genetic mechanism that is likely to drive mutations that can lead to cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!